Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipiocis for Hepatocellular Carcinoma Adjuvant Treatment
NCT00116454Phase 3Completed
- Sponsor
- ANRS
- Start
- Jul 2005
- Primary completion
- Aug 2013
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of iodine-131-labeled lipiodol in hepatocellular carcinoma (HCC) (2 arms), sponsored by ANRS. Primary endpoint: Percentage of tumoral recurrence at 24 months. Started Jul 2005; status: completed.
02
Drugs
iodine-131-labeled lipiodol
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00116454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116454.